EP2509424A4 - Composés inédits d'oxadiazole - Google Patents
Composés inédits d'oxadiazoleInfo
- Publication number
- EP2509424A4 EP2509424A4 EP10836346.6A EP10836346A EP2509424A4 EP 2509424 A4 EP2509424 A4 EP 2509424A4 EP 10836346 A EP10836346 A EP 10836346A EP 2509424 A4 EP2509424 A4 EP 2509424A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxadiazole compounds
- novel oxadiazole
- novel
- compounds
- oxadiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26767909P | 2009-12-08 | 2009-12-08 | |
PCT/US2010/046424 WO2011071570A1 (fr) | 2009-12-08 | 2010-08-24 | Composés inédits d'oxadiazole |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2509424A1 EP2509424A1 (fr) | 2012-10-17 |
EP2509424A4 true EP2509424A4 (fr) | 2013-09-04 |
Family
ID=44145850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10836346.6A Withdrawn EP2509424A4 (fr) | 2009-12-08 | 2010-08-24 | Composés inédits d'oxadiazole |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2509424A4 (fr) |
JP (1) | JP2013512951A (fr) |
CN (1) | CN102762102A (fr) |
AR (1) | AR077908A1 (fr) |
CA (1) | CA2783851A1 (fr) |
MX (1) | MX2012006667A (fr) |
TW (1) | TW201120016A (fr) |
UY (1) | UY32853A (fr) |
WO (1) | WO2011071570A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE036519T2 (hu) | 2007-08-13 | 2018-07-30 | Monsanto Technology Llc | Készítmények és eljárások nematódák irtására |
US8729109B2 (en) | 2011-09-08 | 2014-05-20 | Allergan, Inc. | 3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators |
BR112015023161B1 (pt) | 2013-03-15 | 2022-11-16 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-4-ila |
CN107614491A (zh) * | 2014-06-26 | 2018-01-19 | 蒙纳什大学 | 酶相互作用剂 |
JP7427658B2 (ja) * | 2018-09-18 | 2024-02-05 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのシクロペンチル酸 |
WO2020060916A1 (fr) * | 2018-09-18 | 2020-03-26 | Bristol-Myers Squibb Company | Acides cycloheptyliques utilisés comme antagonistes de lpa |
CN109369620B (zh) * | 2018-12-22 | 2020-04-14 | 山东大学 | 吡啶类化合物及其制备方法与抗胃癌应用 |
CN109776443B (zh) * | 2019-03-25 | 2022-09-27 | 上海万巷制药有限公司 | 一种具有抗氧化作用的噁二唑类化合物及其制备方法 |
JP2023502794A (ja) | 2019-11-19 | 2023-01-25 | モダグ ゲーエムベーハー | α-シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物 |
UY38964A (es) | 2019-11-25 | 2021-06-30 | Novartis Ag | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas |
CN115260173A (zh) * | 2021-04-30 | 2022-11-01 | 厦门宝太生物科技股份有限公司 | 环戊烷并吲哚类支链酸衍生物及其制备方法和应用 |
CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
WO2023118253A1 (fr) * | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dérivés d'acide cyclohexane utilisés en tant qu'inhibiteurs du récepteur de lpa |
CN116444454B (zh) * | 2023-06-16 | 2023-09-12 | 中国医学科学院医药生物技术研究所 | N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007080542A1 (fr) * | 2006-01-11 | 2007-07-19 | Actelion Pharmaceuticals Ltd | Nouveaux derives de thiophene utilises en tant qu’agonistes des recepteurs s1p1/edg1 |
WO2008029370A1 (fr) * | 2006-09-08 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs |
WO2009109904A1 (fr) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Nouveaux dérivés d'aminométhylbenzène |
WO2010148650A1 (fr) * | 2009-06-26 | 2010-12-29 | Glaxo Group Limited | Dérivés hétéroaryliques à 5 chaînons utilisés comme agonistes de récepteurs à la sphingosine-1-phosphate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007251282A1 (en) * | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
-
2010
- 2010-08-20 TW TW099128025A patent/TW201120016A/zh unknown
- 2010-08-23 AR ARP100103076A patent/AR077908A1/es unknown
- 2010-08-23 UY UY0001032853A patent/UY32853A/es not_active Application Discontinuation
- 2010-08-24 WO PCT/US2010/046424 patent/WO2011071570A1/fr active Application Filing
- 2010-08-24 EP EP10836346.6A patent/EP2509424A4/fr not_active Withdrawn
- 2010-08-24 JP JP2012543093A patent/JP2013512951A/ja not_active Withdrawn
- 2010-08-24 MX MX2012006667A patent/MX2012006667A/es not_active Application Discontinuation
- 2010-08-24 CA CA2783851A patent/CA2783851A1/fr not_active Abandoned
- 2010-08-24 CN CN2010800633803A patent/CN102762102A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007080542A1 (fr) * | 2006-01-11 | 2007-07-19 | Actelion Pharmaceuticals Ltd | Nouveaux derives de thiophene utilises en tant qu’agonistes des recepteurs s1p1/edg1 |
WO2008029370A1 (fr) * | 2006-09-08 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs |
WO2009109904A1 (fr) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Nouveaux dérivés d'aminométhylbenzène |
WO2010148650A1 (fr) * | 2009-06-26 | 2010-12-29 | Glaxo Group Limited | Dérivés hétéroaryliques à 5 chaînons utilisés comme agonistes de récepteurs à la sphingosine-1-phosphate |
Non-Patent Citations (1)
Title |
---|
See also references of WO2011071570A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2783851A1 (fr) | 2011-06-16 |
UY32853A (es) | 2011-06-30 |
TW201120016A (en) | 2011-06-16 |
CN102762102A (zh) | 2012-10-31 |
AR077908A1 (es) | 2011-09-28 |
MX2012006667A (es) | 2012-10-15 |
WO2011071570A1 (fr) | 2011-06-16 |
EP2509424A1 (fr) | 2012-10-17 |
JP2013512951A (ja) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0919423D0 (en) | Novel compounds | |
EP2483254A4 (fr) | Composés inédits | |
GB0905955D0 (en) | Novel compounds | |
EP2509424A4 (fr) | Composés inédits d'oxadiazole | |
EP2512242A4 (fr) | Nouveaux composés | |
GB0910674D0 (en) | Novel compounds | |
GB0910691D0 (en) | Novel compounds | |
GB0911130D0 (en) | Novel compounds | |
GB0910689D0 (en) | Novel compounds | |
GB0910009D0 (en) | Novel compounds | |
GB0910688D0 (en) | Novel compounds | |
GB0907118D0 (en) | Novel compounds | |
GB0907820D0 (en) | Novel compounds | |
GB0906577D0 (en) | Novel compounds | |
GB0906578D0 (en) | Novel compounds | |
GB0907104D0 (en) | Novel compounds | |
GB0907105D0 (en) | Novel compounds | |
GB0907106D0 (en) | Novel compounds | |
GB0907107D0 (en) | Novel compounds | |
GB0907112D0 (en) | Novel compounds | |
GB0907113D0 (en) | Novel compounds | |
GB0907114D0 (en) | Novel compounds | |
GB0907116D0 (en) | Novel compounds | |
GB0907117D0 (en) | Novel compounds | |
GB0906288D0 (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120703 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130802 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 487/04 20060101ALI20130729BHEP Ipc: A61K 31/41 20060101ALI20130729BHEP Ipc: C07D 471/04 20060101ALI20130729BHEP Ipc: A01N 43/82 20060101AFI20130729BHEP Ipc: C07D 413/12 20060101ALI20130729BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140301 |